&lt;p&gt;Plasma long noncoding RNAs PANDAR, FOXD2-AS1, and SMARCC2 as potential novel diagnostic biomarkers for gastric cancer&lt;/p&gt;

Yang, Zixian; Sun, Yanan; Rong-feng, Liu; Shi, Yanhong; Ding, Shigang

doi:10.2147/cmar.s201935

Cited by 26 publications

(13 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… a CA19-9 in pancreatic cancer:[ 89 , 90 , 92 , 96 , 97 , 99 , 101 – 103 , 105 – 107 , 109 , 110 , 112 – 114 , 116 – 118 , 121 – 127 , 129 , 132 , 133 , 135 , 137 – 139 , 170 ] b CA19-9 in gastric cancer:[ 25 , 27 , 30 – 32 , 34 , 38 , 46 , 52 , 53 , 57 – 59 , 65 , 74 , 78 , 84 , 168 , 170 , 171 ] c CEA in gastric cancer: [ 25 , 26 , 30 – 32 , 34 , 38 , 46 , 48 – 50 , 52 , 53 , 56 – 59 , 65 , 73 – 75 , 78 , 80 , 84 , …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Introduction Detecting upper gastrointestinal (GI) cancers in primary care is challenging, as cancer symptoms are common, often non-specific, and most patients presenting with these symptoms will not have cancer. Substantial investment has been made to develop biomarkers for cancer detection, but few have reached routine clinical practice. We aimed to identify novel biomarkers for upper GI cancers which have been sufficiently validated to be ready for evaluation in low-prevalence populations. Methods We systematically searched MEDLINE, Embase, Emcare, and Web of Science for studies published in English from January 2000 to October 2019 (PROSPERO registration CRD42020165005). Reference lists of included studies were assessed. Studies had to report on second measures of diagnostic performance (beyond discovery phase) for biomarkers (single or in panels) used to detect pancreatic, oesophageal, gastric, and biliary tract cancers. We included all designs and excluded studies with less than 50 cases/controls. Data were extracted on types of biomarkers, populations and outcomes. Heterogeneity prevented pooling of outcomes. Results We identified 149 eligible studies, involving 22,264 cancer cases and 49,474 controls. A total of 431 biomarkers were identified (183 microRNAs and other RNAs, 79 autoantibodies and other immunological markers, 119 other proteins, 36 metabolic markers, 6 circulating tumour DNA and 8 other). Over half ( n = 231) were reported in pancreatic cancer studies. Only 35 biomarkers had been investigated in at least two studies, with reported outcomes for that individual marker for the same tumour type. Apolipoproteins (apoAII-AT and apoAII-ATQ), and pepsinogens (PGI and PGII) were the most promising biomarkers for pancreatic and gastric cancer, respectively. Conclusion Most novel biomarkers for the early detection of upper GI cancers are still at an early stage of matureness. Further evidence is needed on biomarker performance in low-prevalence populations, in addition to implementation and health economic studies, before extensive adoption into clinical practice can be recommended. Electronic Supplementary Material The online version of this article (10.1007/s12325-020-01571-z) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

“…c CEA in gastric cancer: [ 25 , 26 , 30 – 32 , 34 , 38 , 46 , 48 – 50 , 52 , 53 , 56 – 59 , 65 , 73 – 75 , 78 , 80 , 84 , 168 , 170 , 171 ]…”

Section: Resultsmentioning

confidence: 99%

Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Besides, Rong et al established that FOXD2-AS1 which functions as a tumor inducer via modulating WNT signaling pathway was also signi cantly up-regulated through lung cancer progression [19]. Furthermore, Ziwei Yang and colleagues showed that plasma levels of FOXD2-AS1 might be appropriate diagnostic biomarkers for gastric cancer [4]; further indicating the value of FOXD2-AS1 as a diagnostic and prognostic target for human cancers, including CRC.…”

Section: Discussionmentioning

confidence: 99%

“…Early detection of CRC has been shown to increase the 5-year survival rates to 90% after removal of the local tumor, while detection in advanced and metastatic stages lowers it to 10% [2,3]. Therefore, there is a constant need to is necessary to explore new therapeutic and diagnostic targets with high sensitivity and speci city [4].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of lncRNA FOXD2-AS1 expression as a diagnostic biomarker in CRC

Shalmashi

Safaie

Shanehbandi

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Colorectal cancer (CRC) is still considered one of the prevalent cancers worldwide. Investigation of potential biomarkers for early detection of CRC is essential for the effective management of patients using therapeutic strategies. Considering that, this study was aimed to examine the changes in lncRNA FOXD2-AS1 expression through colorectal tumorigenesis. Material and Methods Fifty CRC tumor tissues and fifty adjacent normal tissue samples were prepared and involved in the current study. Total RNA was extracted from the samples and then reverse transcribed to complementary DNA. Next, the expression levels of lncRNA FOXD2-AS1 were evaluated using real-time PCR in CRC samples compared to normal ones. Also, receiver operating characteristic curve (ROC) analysis was used to evaluate the diagnostic value of FOXD2-AS1 for CRC. Results The obtained results showed that the expression level of FOXD2-AS1 gene was significantly (p < 0.0001) up-regulated in tumor tissues compared to normal marginal tissues. Also, a significant correlation was observed between higher the expression of FOXD2-AS1and the differentiation of tumor cells. Furthermore, ROC curve analysis estimated an AUC value of 0.59 for FOXD2-AS1, suggesting its potential as a diagnostic target. Conclusion Taken together, the current study implied that tissue-specific upregulation of lncRNA FOXD2-AS1 might be appropriate diagnostic biomarkers for CRC. Nonetheless, m studies are needed to validate these results and further illustrate FOXD2-AS1 function through colorectal tumorigenesis.

show abstract

“…Increasing shreds of evidence have proven that lncRNAs were implicated in a variety of biological processes and have shown altered expression patterns in specific cancer types (13)(14)(15)(16). Given the relatively stable local secondary structures and high cancer specificity, lncRNAs may act as an ideal class of biomarkers with potential applications in survival prediction (17)(18)(19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

Individualized Prediction of Survival by a 10-Long Non-coding RNA-Based Prognostic Model for Patients With Breast Cancer

Yang

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Deregulations of long non-coding RNAs (lncRNAs) have been implicated in the progression of breast cancer (BC). However, the prognostic values of those lncRNAs in BC remain elusive. This study aimed at constructing a lncRNA-based prognostic model to improve the clinical management of BC. Systematic investigation of lncRNA expression profiles and clinical data from The Cancer Genome Atlas (TCGA) database were utilized to establish a 10-lncRNA signature. The prognostic signature efficiently discriminated patients with significantly different prognosis regardless of intrinsic molecular subtypes and tumor-node-metastasis (TNM) stage. A combined model was constructed by multivariate Cox proportional hazards regression (CPHR) analysis, which combined the lncRNA-based signature with certain clinical risk factors (TNM stage, age, and human epidermal growth factor receptor 2 status). This model predicted a survival probability that closely corresponds to the actual survival probability. With respect to the entire set, the time-dependent receiver-operating characteristic curves revealed that the area under the curve of this model was the highest than any of the clinical risk factors. Moreover, functional enrichment analysis indicated that the molecular signature was mainly involved in DNA replication, which was firmly related to BC tumorigenesis. Consistent with the discovery, the knockdown of LHX1-DT, one of the 10 prognostic lncRNAs, attenuated the proliferation of BC cells in vitro and in vivo. Taken together, our study constructed a novel 10-lncRNA signature for prediction prognosis, and the signature-based model could provide new insight into accurate management of BC patients.

show abstract

<p>Plasma long noncoding RNAs PANDAR, FOXD2-AS1, and SMARCC2 as potential novel diagnostic biomarkers for gastric cancer</p>

Cited by 26 publications

References 47 publications

Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers: A Systematic Review

Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers: A Systematic Review

Evaluation of lncRNA FOXD2-AS1 expression as a diagnostic biomarker in CRC

Individualized Prediction of Survival by a 10-Long Non-coding RNA-Based Prognostic Model for Patients With Breast Cancer

Contact Info

Product

Resources

About